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Introduction
Diabetes Mellitus is a chronic illness that increases the risk of
microvascular complication and results in blindness, kidney failure,
and lower extremity amputations, and macrovascular complication
of coronary artery disease and stroke. In the State of Hawaii, an
estimated eight to ten percent of the population have diabetes
mellitus, i.e. about 80,000 to 100,000 individuals, primarily adults
with type 2 diabetes. Alarmingly, native Hawaiian adults over 30
years of age have been identified with a diabetes prevalence rate of
20%. Several studies clearly document the increasing rate of diabe
tes among native Hawaiians over the past 30 years. Based on recent
data, it is estimated that about 20,000 adult native Hawaiians (18-
20% prevalence rate) have diabetes mellitus) It would appear that
interventions to prevent diabetes and diabetic complications receive
the highest priority in the effort to improve the health status of the
people of Hawaii, especially native Hawaiians.
Two major intervention trials have clearly demonstrated that
intensive glycemic control prevents and delays the development of
microvascular complication in patients with type 1 diabetes: the
Diabetes Control and Complications Trial (DCCT) and the Stockholm
Diabetes Intervention Study (SDIS).23 Results from a randomized
prospective 6-year study in Japan show that intensive insulin treat
ment of type 2 diabetic patients reduces microvascular complica
tion.4Many studies have demonstrated the association of hypergly
cemia with macrovascular complications of ischemic heart disease
and stroke and increased cardiovascular disease risk factors, e.g.,
dyslipidemia, hypertension, and obesity. The 12-year cardiovascu
lar mortality of men screened in the Multiple Risk Factor Interven
tion Trial (MRFIT) showed that diabetic patients consistently had
higher cardiovascular mortality than non-diabetic men matched for
one or more of the major risk factors for CVD.5 The data from the
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MRFIT study suggests that glycemic control in type 2 diabetes is an
important and independent risk factor for CVD. Still, results of
randomized controlled clinical trials that examines the effect of
normalized blood glucose levels in type 2 diabetic patients on
macrovascular endpoints have been inconclusive and somewhat
controversial.6’7
The United Kingdom Prospective Diabetes Study (UKPDS) is the
longest and largest prospective clinical study of type 2 diabetics.
Started in 1977, newly diagnosed type 2 diabetic patients were
recruited. The aim was to determine whether an “active” pharmaco
logical program (intensive) of hyperglycemic management results
in a better long-term outcome than a diet and exercise program
(conventional).
The UKPDS was designed to answer the following questions:
I) If high blood glucose levels are more intensively treated in
people with type 2 diabetes, could serious complications of
diabetes be prevented or delayed, and are there any advantages
or disadvantages of the various pharmacological interventions
that lower blood glucose levels?
2) Would intensive treatment of high blood pressure in type 2
diabetic patients reduce the risk of diabetes complications, and
are there any advantages or disadvantages of the various
pharmacological interventions that lower blood pressure?
UKPDS Study Design and Results
Between 1977 and 1991, 7616 patients with newly diagnosed type
2 diabetes, ages 25-65 were referred by general practitioners to the
23 participating UKPDS hospitals, and 5102 patients were recruited
into the study. After a 3-month diet program, 4209 patients were
enrolled into the study of which 3867 patients who had a mean
fasting plasma glucose concentrations of 6.1-15 mmoLlL (110—270
mg/dl) were randomly assigned to sulfonylurea (chiorpropamide,
glibenclamide, glipizide), insulin, and conventional treatment groups
(baseline characteristics are presented in Table I). Patients in the
conventional treatment group attended clinic every 3 months and
received dietary counseling with the aim of maintaining near-
normal body weight and maintain FPG levels below 15 mmolJL
(270 mg/dl) without symptoms of hyperglycemia. If marked hyper
glycemia or symptoms occurred, patients were secondarily random
ized to sulfonylurea, insulin or metformin treatment. There were
three measures of outcomes for comparison between conventional
and intensive treatment; 1) any diabetes-related endpoint (sudden
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death, death from hyperglycemia or hypoglycemia, fatal or non
fatal myocardial infarction, angina, heart failure, stroke, renal fail
ure, amputation, vitreous hemoffhage, retinopathy requiring photo-
coagulation, blindness in one eye, or cataract extraction), 2) diabe
tes-related death (death from myocardial infarction, stroke, periph
eral vascular disease, renal disease, hyperglycemia or hypoglyce
mia, and sudden death), and 3) all-cause mortality.
of retinopathy requiring photocoagulation.
As expected, patients in the intensive treatment group had signifi
cantly more hypoglycemic episodes than patients in the conven
tional group. The rates of major hypoglycemic episodes (reactions
requiring assistance from others for recovery) per year were 0.7%
with conventional treatment, 1.0% with chlorpropamide, 1.4% with
glibenclamide, and 1.8% with insulin. Additionally, there was
significant weight gain in the intensive group (mean 2.9 kg) than in
the conventional group (p<O.OOI). and patients assigned to insulin
therapy had greater gain (4.0 kg) than those assigned chlorpropam
ide (2.6kg) or glibenclamide (1.7kg).
Intensive treatment with sulfonylureas and
insulin8
The FPG and HbAlc levels in the conventional group increased
steadily from the beginning of the study compared to the intensive
group which had an initial decline in FPG and HbAlc levels within
the first year, but subsequently increased with time similar to that
seen in the conventional group. Median HbAlc for each 5-year
period of follow-up in the intensive and conventional groups were
6.6% and 7.4% respectively for the first period, 7.5% and 8.4% for
the second, and 8.1% and 8.7% for the third period. The median 10-
year HbAlc values with chlorpropamide (6.7%), glibenclamide
(7.2%), or insulin (7.1%) treatments were each significantly lower
than with conventional treatment (7.9%).
The data from 2729 patients intensively treated with sulfonylureas
and/or insulin achieved an average HbAlc level of 7% (6.2-8.2)
over 10 years and showed a 12% lower rate of diabetes-related
endpoints than 1138 patients treated with conventional diet and
exercise program with an average HbAlc level of 7.9% (6.9-8.8).
Most of the risk reduction was attributed to the 25% lower rate of
microvascular endpoints; retinopathy (requiring photocoagulation)
and albuminuria (Figure 1). There was a 16% reduction in myocar
dial infarction rate in the intensive treatment group as compared to
the conventional group, but this difference was not statistically
significant (p=O.O6). Differences in any microvascular or
macrovascular endpoint were not observed between the three agents
used in the intensive treatment group with the exception of the
chlorpropamide treatment group which failed to show reduced rate
Metformin treatment in overweight patients9
Insulin resistance is a key feature of type 2 diabetes, especially when
obesity is present. Metformin is a biguanide that decreases blood
glucose concentration by mechanisms different from those of sulfo
nylurea or insulin yet poorly understood. Treatment with metformin
results in suppression of endogenous hepatic glucose production
and enhanced glucose uptake by muscle [10]. In the UKPDS, 1704
newly diagnosed, overweight (> 120% ideal body weight) type 2
diabetic patients were randomized to receive either conventional
treatment, primarily diet control (n=41 I), or treatment with metformin
(n=342), chlorpropamide (n=265), glibenclamide (n=277), or insu
lin (n=409). Treatment in the metformin group was started with one
850 mg tablet per day. then twice a day and then 1700 mg in the
morning and 850mg with the evening meal. In the metformin group,
there was a decrease in FPG and HbAlc levels in the first year, with
a subsequent gradual rise in both variables. The median HbAI c level
during the 10 years of follow-up was 7.4% in the metformin group
and 8.0% in the conventional group. The metformin group showed
significant 32% lower risk of any diabetes-related endpoint, includ
ing a 36% reduction in diabetes-related death and all-cause mortality
as compared to the conventional group. Furthermore, a significant
lower risk of myocardial infarction (39%) and macrovascular dis
eases (30%) in the metformin group (myocardial infarction, sudden
death, angina, stroke, and peripheral disease) was observed (Figure
2). Similar macrovascular complication risk reduction was seen in
the metformin group as compared to the sulfonylurea or insulin
Table 1. Baseline characteristics of patients in conventional and intensive-treatment
groups
Character Conventional Intensive
(n=1138) (n2729)
Age 53.4 53.2
Sex
Male/Female 705/433 649/444
Ethnicity
(%Caucasian) 81 81
Weight (kg) 78.1 77.3
Body mass index (kg/m2) 27.8 27.5
Blood Pressure 135/82 135/83
Fasting plasma glucose(mmol/L) 8.0 (7.1.9.6) 8.1 (7.1.9.8)
(mg/dl)
HbA1C 7.05 7.09
LDL cholesterol (mmol/L) 3.5 3.5
Serrogate clinical endpoints
Retinopathy (%) 36 36
Proteinuria (%) 2.1 1.7
Plasma Creatinine (mmol/L) 81(66.99) 82 (67.1 00)
(mg/dL) 0.92 0.93
Retinal
Photocoagulation
Figure 1. Relative Risk Reduction of the Aggregate and Single Endpoints of
Intensive versus Conventional Treatment
Any DM- Stroke Weight
related HbAlc
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groups. The rate of major hypoglycemic episodes was lower than
patients taking sulfonylureas (1.2% in chlorpropamide group, 1.0%
in glibenclarnide group, 2.0% in insulin group and 0.6% in metformin
group). There was no significant change in body weight between
metformin group and conventional group.
Additional 1234 patients, both non-overweight and overweight,
who were initially started on sulfonylurea therapy, were randomly
assigned to early addition of metformin or continued sulfonylurea
treatment if blood glucose profiles deteriorated. The comparison of
the combination treatment arms with and without the addition of
metformin to sulfonylurea-treated patients produced some unex
pected findings. The addition of metformin to sulfonylurea was
associated with a 96% increased risk of diabetes-related death and
60% all-cause deaths as compared to the sulfonylurea only group.
The investigators completed a meta-analysis and an epidemiologi
cal analysis of these results and could not substantiate the finding.
Still, the data demonstrated a nearly two fold increase in mortality
with combination metformin-sulfonyl urea therapy irrespective of
glycemic control.
Blood pressure control and diabetic complica
tioni 11J2
The UKPDS also compared macrovascular and microvascular
complications with blood pressure control in a subgroup of 1,148
hypertensive type 2 diabetic patients. 758 patients were allocated to
a “tight” control group aimed to keep blood pressure < 150/85 mm
Hg, and 390 patients to a “less tight” control group targeting blood
pressure < 180/105 mm Hg. Captopnl, an Angiotensin Converting
Enzyme (ACE) inhibitor or atenolol, a selective 3-adrenergic block
ing agent was the anti-hypertensive medications used in this study.
400 patients were given 50mg twice daily ofcaptopnl with a starting
dose of 25mg twice daily, and 358 patients were treated with a daily
dose of 50mg atenolol, which was increased to 100mg as necessary.
If blood pressure goals were not met in either medication group, the
other agent was added to the regimen.
During the median follow-up period of 8.4 years, mean blood
pressure in the “tight” blood pressure group was 144/82 mm Hg
compared with 154/87 mm Hg in the “less tight” control group. The
“tight” control group had a 24% reduction in diabetes-related
endpoints; 32% reduction in deaths due to diabetes, 44% fewer
strokes, and 37% fewer microvascular endpoints, primarily the
number of retinal photocoagulation and the development of diabetic
maculopathy, which is the main cause of visual impairment in type
2 diabetes. This finding from the UKPDS is the first known report
in type 2 diabetes which demonstrate that interventions offering
“tight” blood pressure control reduces the risk of diabetic complica
tions.
The results of blood pressure treatment with captopril or atenolol
failed to show specific advantages or disadvantages in preventing
the complications of type 2 diabetes. There was a 37% progression
rate for retinopathy in each group compared to a rate of 51% in the
“less tight” control group, and differences were not observed be
tween the captopril and atenolol groups for deterioration of visual
acuity. The progression rate of albuminuria and proteinuna and the
occurrence of two-fold increase in plasma creatinine concentration
and end stage renal disease were similar between these two medica
tion groups. After the first four years of treatment, more patients in
the atenolol group discontinued medication, because of impaired
peripheral circulation or bronchospasm. Four percent of patients in
the captopnl group discontinued treatment because of side effects
with coughing, and the ACE inhibitor were withdrawn in five
patients due to increasing creatinine levels. There was no differ
ences found in the incidence of myocardial infarction, strokes, heart
failure, or angina between the two medication groups.
Implications for Patient Care
The UKPDS is a landmark study of type 2 diabetic patients produc
ing very useful data thatis translatable to clinical practice. This study
has shown that “tight control” of blood glucose levels in type 2
diabetic patients will dramatically reduce the incidence of microvas
cular complications. Many prospective studies have suggested that
hyperinsulinemia is a risk factor for cardiovascular disease in people
without diabetes, although these studies do not distinguish between
insulin and insulin resistance as the factor associated with increased
cardiovascular risk. The University Group Diabetes Program
(UGDP), a similarly large prospective study (1,027 patients en
rolled) was conducted during a period between 1960- 1966 to
evaluate the efficacy of glycemic control in type 2 diabetes in the
prevention ofcardiovascular complication.’3The result of the UGDP
study was highly controversial because it failed to demonstrate any
benefit from oral hypoglycemic agent and insulin therapies. More
over, the data from UGDP study showed a significantly higher
cardiovascular mortality rate in the tolbutamide-treated group than
in the placebo-treated group. Over the years, this unexpected finding
has elicited many hypotheses that could explain the tolbutamide
effect. The mechanism of sulfonylurea toxicity includes myocardial
damage from inhibition of ATP-K+ channel opening in the presence
of myocardial ischemia due to sulfonylurea binding to the cardio
vascular SUR2 receptor, an event that could also increase the
likelihood of ventricular arrhythmia.’4The UKPDS did not demon
strate specific adverse cardiovascular effects with chlorpropamide,
glibenclamide, or insulin treatment. Thus, the UKPDS appears to
clearly dispel the notion of cardiovascular disease toxicity with
sulfonylurea or insulin therapy.
The most striking and unexpected finding from the UKPDS is the
results from obese type 2 diabetic patients. Metformin treatment
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Figure 2. Relative Risk Reduction in the incidence of Clinical
Endpoints of Metformin versus Conventional Treatment
Any DM- All Cause Myocardial Stroke
related Mortality Infarction
Endpoint
Percent I I I
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reduced diabetes-related endpoints, diabetes-related death, and all-
cause mortality when compared with conventional treatment. Given
the same HIJA 1C levels obtained the effect of metformin in reducing
the risk for diabetes-related complication and all-cause mortality is
difficult to explain on the basis of glycemic control. The improve
ments in cardiovascular disease outcomes might be due to anti
atherogenic effects with metformin, which includes improved fi
brinolysis, decreased platelet aggregation. increased erythrocyte
deformability, and decreased lipid incorporation into vessel walls
which might explain the decreased arterial wall smooth muscle cell
growth, and restoration of arterial vasodilatation. The investigators
of the UKPDS “boldly” concluded that metforniin might be consid
ered first-line treatment in overweight type 2 diabetic patient. The
results of metformin treatment suggest that thiazolidinediones (a
new class of anti-hyperglycemic agents), which also enhances
insulin sensitivity, could produce similar results.’5 The use of
metformin in combination with a sulfonylurea has shown an in
crease in risk of diabetes-related and all-cause mortality. This
contradictory and controversial finding may be a consequence of the
analytical strategy and have raised new questions for the next
generation of clinical trials.’6The contradiction in the results is the
finding of increased mortality with combined used despite clearly
reduced morbidity and mortality when used separately. The contro
versial consideration is the fact that many physicians are now using
this combination for patients with diabetes who failed to reach
targeted goals with one agent. American Diabetes Association
believes this analytical approach does not resolve the discrepancy in
the results with metformin, that is, it does not provide assurance that
the combination is safe or prove that it is unsafe. If there is some
specific mechanism of adverse interaction between metformin and
sulfonylurea drugs, this can only be definitely determined in a new,
appropriately designed, randomized, placebo-controlled trial. Until
such a trial is concluded, American Diabetes Association does not
recommend any change in the current guidelines for the use of
metformin as monotherapy or in combination with sulfonylurea
drugs.’7
In addition to adequate control ofblood glucose levels, aggressive
control of blood pressure has shown positive effect in all diabetes-
related complications. Hypertension is one of the risk factors for
cardiovascular and renal disease and commonly associated with
type 2 diabetes. At the age of 45 years, approximately 40% of
patients with type 2 diabetes are hypertensive and this proportion
rises to an estimated 60% prevalence by age 75 years. The negative
inotropic effect of atenolol might have been expected to increase the
incidence ofheart failure, but the protection against heart failure was
the same for atenolol as for captopril. The similar effect of captopril
and atenolol on clinical endpoints suggests either that both J3-
adrenergic blockers and ACE inhibitor have specific beneficial
effects or that the decrease in blood pressure is the important factor
and not the type of treatment. These results are interesting given the
current debate over benefit from ACE inhibitor treatment for pre
venting the progression of diabetic nephropathy. The suggestion
that ACE inhibitors have a specific renal protective effect in the
treatment of type 2 diabetes is not supported in this study. These
results clearly demonstrate the renal protective effect of reducing
blood pressure, which decrease capillary perfusion, transcapillary
leakage of albumin, and decrease damage to glomeruli. This study
shows that atenolol and captopril are equally effective and safe in
lowering blood pressure and reducing the risk of complications in
type 2 diabetic patients. In the UKPDS, lipid levels were not
included in the data analysis and may prove to be a contributing
factor to some of the results presented.
In summary, how do we translate the UKPDS results? The
American Diabetes Association believes that the evidence confirms
what many investigators have suspected all along that people with
type 2 diabetes and their health care teams should strive diligently
to lower blood glucose levels as close to normal as possible. Thus,
intensive therapy of type 2 diabetes with sulfonylureas and insulin
is beneficial despite the associated weight gain, and not a detriment
to reducing cardiovascular outcomes. The UKPDS data supports the
use of metformin as a starting agent in overweight patients as
monotherapy and perhaps could be extended to other insulin sensi
tizers, the thiazolidinedione.
The importance of controlling cardiovascular disease risk factors
in diabetic patients cannot be over emphasized, especially blood
pressure control as reported in the UKPDS. Still, the finding ofequal
efficacy between captopril and atenolol does not fully support the
abandonment of ACE inhibitors for cheaper, generic J3-adrenergic
blockers in treating hypertension among diabetics. Along with the
potential renal protective effect of ACE inhibitors, these agents
minimally affect plasma lipid levels, enhances myocardial contrac
tility in CHF that is commonly seen in diabetes, and does not induce
bronchospasm. American Diabetes Association concluded that both
drugs used to reduce hypertension are equally effective and safe, and
either can be used with great benefit to treat uncomplicated hyper
tension in patients with type 2 diabetes. Both conventionally and
intensively treated patients in the blood glucose study equally
benefited from blood pressure lowering. Likewise, the tightly and
less tightly controlled blood pressure study patients had equal
benefit from blood glucose lowering. Thus, both hyperglycemia and
hypertension should be vigorously treated when they occur together
with an expectation that reductions in microvascular and cardiovas
cular outcomes will be additive [17]. Lastly, other cardiovascular
disease risk factor analysis (e.g. dyslipidemia, cigarette smoking,
nutrition and exercise modification) should also be emphasized
since the clinical management of type 2 diabetes requires a multi-
modal and comprehensive approach.
What is clear from the UKPDS is that hyperglycemia treatment
impacts microvascular and macrovascular outcomes in patients
with diabetes, even with less than a one percent reduction in HbAlc
levels. The UKPDS findings more clearly demonstrate the impor
tance of addressing the other CVD risk factors in type 2 diabetes
mellitus to reduce secondary complications. The results from the
UKPDS define the management of type 2 diabetes mellitus as a
complex disorder, engaging the physician to examine more of the
patient than hyperglycemia.
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Classified Notices
To place a classified notice:
HMA members—Please send a signed and type
written ad to the HMA office. As a benefit of member
ship, HMA members may place a complimentary one
time classified ad in HMJ as space is available.
Nonmembers.—Please call 536-7702 for a non-
member form. Rates are $1 50 a word with a minimum
of 20 words or $30. Not commissionable. Payment
must accompany written order.
Office Space
ALA MOANA BLDG.—PHYSICIANS WANTEDto share
space and support services. Interest in physical rehab.
preferred. We have flexible rental arrangements start
ing at one half-day per week. Run your practice with no
fixed overhead. Contact Dr. Speers, REHABILITA
TION ASSOCIATES, 955-7244.
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PIONEER PLAZA KALIHI.—CENTRALLY LOCATED
in established business/residential area. Only contem
porary building in area with high traffic, lots of parking,
good tenant mix including medical and dental. Spaces
from 150-20,000 sf. Excellent clinic or group practice
spaces. Call 955-7377.
Wanted
PSYCHIATRIST.— Kaneohe residential Program for
adolescents seeks consultant two half-days per month.
Schedule, duties, compensation negotiable. Contact
Administrator: RAINBOW HOUSE 239-2399.
HAWAII PERMANENTE MEDICAL GROUP.— Kaiser
Permanente. Hawaii’s most established multi-spe
cialty group of 300 physicians recruiting for:
• BC/BE internal medicine hospitalists, staff and
Locum Tenen positions available, servicing all hospi
talized patients in 200-bed Kaiser hospital on Oahu,
position(5) immediately available.
• BC/BE general internist for busy outpatient clinic,
inpatient duties (CCU/ICU/ventilator management) and
call, practice based in Kona on the Big Island (affiliated
with Kona Community Hospital.) Position available
mid-August 2000.
Applicants must have a commitment to quality care,
patient advocacy, and involvement in patient and
professional education. We offer competitive salary,
comprehensive benefits, relocation assistance and
more.
Send CV to: Physician Recruitment, HPMG, 3288
Moanalua Road, Honolulu, HI 96819 or Fax (808)834-
3994. EOE
URGENT CARE CALL-IN PHYSICIANS.— SRAUB
CLINIC is seeking primary care or emergency medi
cine call-in physicians for its Urgent Care and Doctors
On Call Clinics. An excellent opportunity for extra
hours or periodic work. Fax CV to: Ellen Saiki, Physi
cian Recruitment Coordinator, Straub Clinic and Hos
pital, 888 South King Street, Honolulu, HI 96813; FAX
(808) 522-4038.
ASSISTANT PROFESSOR, 2 positions, Position #88860T and 85025T, Geriatric
Medicine Program, Dean’s office, UH John A. Burns School of Medicine, F/T,
temporary, non-tenurable, to begin approx. 08/00 pending position clearance and
funding availability. Duties: (Pos. #88860T): Provide clinical services at the Hawaii
State Hospital; teach medical students, residents, fellows, and interdisciplinary continu
ing education. (Pos. #85025T): Develop an academic program in end-of-life care and
or Geriatric Medicine, undertake didactic teaching, clinical teaching services, research,
and publications. MQ: (Pos. #88860T): M.D. or D.C. degree; board eligible or board
certified in Internal Medicine by the ABIM, eligible for Hawaii license, demonstrated
ability in teaching. (Pos. #85025T): Same as Pos. #88860T plus two-year fellowship and
CAQ in Geriatric Medicine. Mm Annual Sal: $78,924. To Apply: Send updated CV,
bibliography, letter of application, and 3 letters of recommendation to: Patricia Lanoie
Blanchette, M.D., MPH, Director, Geriatric Medicine Program, 347 No. Kuakini St.,
HPM 9, Honolulu, HI 96817. 808-523-8461; FAX 808-528-1897. Closing Date: July
20. An EEO/AA Institution.
